Management and monitoring are essential elements of the treatment journey
Assess patients' liver function,a platelet count, and troponin-I at baseline and for at least 3 months following infusion as described in the Prescribing Information1
Treat with systemic corticosteroids
To help manage a possible increase in liver aminotransferases, treat all patients with systemic corticosteroids before treatment and continue regimen after treatment1
The importance of multidisciplinary care
Although ZOLGENSMA is a one-time-only infusion, post treatment management and continued SMA care are essential for improving outcomes of children with SMA.
In addition to regular well visits, it is important that patients with SMA receive respiratory, nutritional, and musculoskeletal support, which are fundamental elements of SMA care that can help maximize functional ability.2,3
Because the loss of motor neurons cannot be reversed, this care should begin as early as possible and continue even after treatment.2,3
Patients treated with ZOLGENSMA may still require the following specialized support2,3:
Patient and caregiver support
A resource for caregivers
Help caregivers understand what to expect after treatment and how to maintain proper SMA care. Fill out the Post Treatment Plan and share it with your patient’s family prior to the patient being discharged.